Opening With Innovations in Chronic Lymphocytic Leukemia (CLL): The Practicalities and Potential of Finite Therapy With BTK Inhibitors (BTKi) Platforms

Faculty Affiliations and Disclosures

Chair and Moderator

Paolo Ghia, MD, PhD Full Professor, Medical Oncology Director, Strategic Research Program on CLL Deputy Chairman, Experimental Oncology Division Head, B-Cell Neoplasia Unity Universita Vita-Salute San Raffaele IRCCS Ospedale San Raffaele Milano, Italy

Paolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of: *Consultant and/or Advisor* for Abbvie, Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; Galapagos NV; Janssen Pharmaceuticals, Inc.; and Merck Sharp & Dohme.

Grant/Research Support from Abbvie, Inc.; AstraZeneca; Bristol Myers Squibb and Janssen Pharmaceuticals, Inc.

Speaker for AstraZeneca; BeiGene, Inc.; Galapagos NV; Janssen Pharmaceuticals, Inc. and Merck Sharp & Dohme.

Faculty and Presenter

Nicole Lamanna, MD Professor of Medicine, Leukemia Service Director of the Chronic Lymphocytic Leukemia Program Hematologic Malignancies Section Herbert Irving Comprehensive Cancer Center New York-Presbyterian / Columbia University Medical Center New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of: *Consultant and/or Advisor* for AbbVie Inc.; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC. *Grant/Research Support* from AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty and Presenter

Dr. Lydia Scarfo, MD Strategic Research Program on CLL Universita Vita Salute San Raffaele IRCCS Ospendale San Raffaele Milano, Italy

Dr. Lydia Scarfò, MD, has a financial interest/relationship or affiliation in the form of: *Consultant and/or Advisor* for AbbVie; AstraZeneca; BeiGene, Inc.; Lilly; and Janssen. *Speakers Bureau* participant with Octapharma.